[Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
In 19 patients with recently diagnosed multiple myeloma 3-week cycles of vincristine, BCNU, melphalan, cyclophosphamide and prednisone alternating with interferon were administered over 6-12 months. Results were compared with a control group of 33 myeloma patients treated exclusively with VBMCP cytostatics. In interferon treated patients objective response was more frequent (76%) and median survival time longer (above 35 months).
Gola
A
A
Klinika Hematologii i Chorób Rozrostowych AM, Wrocławiu.
Usnarska-Zubkiewicz
L
L
Wołowiec
D
D
Urbaniak-Kujda
D
D
Kotlarek-Haus
S
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone
Wyniki naprzemiennego leczenia szpiczaka mnogiego--cytostatykami VBMCP i rekombinowanym interferonem alfa-2B.